Infectious complications in patients receiving mobilization chemotherapy for autologous peripheral blood stem cell collection

被引:13
作者
Jillella, AP
Ustun, C
Robach, E
Sertkaya, D
Dipiro, C
Kallab, AM
Brick, WG
Dainer, PM
Kutlar, A
Townsend, AR
Burgess, RE
机构
[1] Med Coll Georgia, Dept Med, Hematol Oncol Sect, Augusta, GA 30912 USA
[2] Med Coll Georgia, Dept Pharm, Augusta, GA 30912 USA
[3] Hacettepe Univ, Dept Stat, TR-06100 Ankara, Turkey
来源
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH | 2003年 / 12卷 / 02期
关键词
D O I
10.1089/152581603321628296
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this retrospective study was to evaluate infectious complications in patients receiving mobilization chemotherapy for stem cell collection prior to autologous peripheral blood stem cell transplantation. An additional goal was to evaluate risk factors associated with the development of infectious complications. At the Medical College of Georgia BMT center, 54 patients were administered mobilization chemotherapy for the purpose of collecting stem cells between June, 1997, and May, 2002. All patients received Filgrastim in addition to chemotherapy, and 50 of 54 patients received prophylactic acyclovir, fluconazole, and ciprofloxacin until neutrophil recovery. The median duration to neutrophil recovery was 11 days. Fourteen of 54 ( 26%) patients developed fever/infections during the mobilization phase. One patient developed both a catheter-related infection and Clostridium difficile colitis, increasing the total number of infectious episodes to 15. Twelve patients had a documented site of infection whereas 2 patients had neutropenic fever with no identifiable source. Eight of the 15 (55%) infections were Gram-positive catheter infections. All the patients were treated successfully with antibiotics. No systemic fungal infections were identified and none of the patients died from complications related to mobilization chemotherapy. Logistic regression was applied for univariate and multivariate analysis and showed that age, sex, diagnosis, neutrophil recovery, disease status, use of salvage chemotherapy, and mobilization regimen used did not affect the infection rate. In our series of 54 patients, 14 patients developed fever/infections during mobilization. Although there is a substantial risk of infectious complications among patients who receive mobilization chemotherapy, it is not clear that prophylactic antibiotics decrease infectious complications. Because the vast majority of infections are Gram-positive catheter infections, it appears reasonable to employ Gram-positive prophylaxis. Controlled studies should be conducted to define the optimum mobilization regimens as well as the optimum combination of prophylactic antibiotics.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 15 条
  • [1] Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer
    Bilgrami, S
    Feingold, JM
    Bona, RD
    Edwards, RL
    Khan, AM
    Rodriguez-Pinero, F
    Khan, IA
    Kazierad, D
    Clive, J
    Tutschka, PJ
    [J]. BONE MARROW TRANSPLANTATION, 2000, 25 (02) : 123 - 130
  • [2] Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies
    Çelebi, H
    Akan, H
    Akçaglayan, E
    Üstün, C
    Arat, M
    [J]. BONE MARROW TRANSPLANTATION, 2000, 26 (02) : 211 - 214
  • [3] DELFAVERO A, 1995, SCAND J INFECT DIS, P34
  • [4] Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma
    Desikan, KR
    Barlogie, B
    Jagannath, S
    Vesole, DH
    Siegel, D
    Fassas, A
    Munshi, N
    Singhal, S
    Mehta, J
    Tindle, S
    Nelson, J
    Bracy, D
    Mattox, S
    Tricot, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1547 - 1553
  • [5] High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer
    Donato, ML
    Gershenson, D
    Ippoliti, C
    Wharton, JT
    Bast, RC
    Aleman, A
    Anderlini, P
    Gajewski, JG
    Giralt, S
    Molldrem, J
    Ueno, N
    Lauppe, J
    Korbling, M
    Boyer, J
    Bodurka-Bevers, D
    Bevers, M
    Burke, T
    Freedman, R
    Levenback, C
    Wolf, J
    Champlin, RE
    [J]. BONE MARROW TRANSPLANTATION, 2000, 25 (11) : 1137 - 1140
  • [6] KLASTERSKY J, 1998, EUR J CANCER CLIN ON, V24, pS35
  • [7] Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells
    Klein, JL
    Rey, PM
    Dansey, R
    Karanes, C
    Abella, E
    Cassells, L
    Hamm, C
    Flowers, M
    Couwlier, C
    Peters, WP
    Baynes, RD
    [J]. BONE MARROW TRANSPLANTATION, 1999, 24 (09) : 959 - 963
  • [8] Knudsen L M, 1996, J Hematother, V5, P399, DOI 10.1089/scd.1.1996.5.399
  • [9] Lee W J, 1994, Prog Clin Biol Res, V389, P421
  • [10] Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study
    Tjan-Heijnen, VCG
    Postmus, PE
    Ardizzoni, A
    Manegold, C
    Burghouts, J
    van Meerbeeck, J
    Gans, S
    Mollers, M
    Buchholz, E
    Biesma, B
    Legrand, C
    Debruyne, C
    Giaccone, G
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (10) : 1359 - 1368